Last reviewed · How we verify

NCT06915103

A Case Report of NMDAR Encephalopathy

Completed Last updated 8 April 2025
What this trial tests

trial testing Magnetic Resonance Imaging (MRI) in Anti-NMDA Receptor Encephalitis in 1 participant. Completed in 19 December 2024.

Timeline
20 June 2024
Primary endpoint
8 July 2024
19 December 2024

Quick facts

Lead sponsorMayo Clinic
StatusCompleted
Study typeOBSERVATIONAL
Enrollment1
Start date20 June 2024
Primary completion8 July 2024
Estimated completion19 December 2024
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Mayo Clinic

Who can join

Adults 34 to 34, female only, with Anti-NMDA Receptor Encephalitis or Mature Teratoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This case illustrates the clinical, radiologic, and histopathologic features of Anti-NMDAR encephalitis and underscores the importance of MRI in detecting ovarian teratomas when pelvic ultrasound is inconclusive.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. A case report of NMDAR encephalopathy - A neurologic condition that a gynecologist can cure.
    Molina MP, Drake E, El-Nashar S, Desai MA, et al · · 2025 · PMID 40273580 · DOI 10.1016/j.ijscr.2025.111219

Verify or expand the search:

Other trials of Magnetic Resonance Imaging (MRI)

Trials testing the same drug.

Other recruiting trials for Anti-NMDA Receptor Encephalitis

Currently open trials in the same condition.

Other Mayo Clinic trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06915103.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing